Tuesday, March 5, 2013

Pilot season: TheWrap's best bets, Part I

NEW YORK (TheWrap.com) - We think we can guess what you'll be watching on TV next season.

As the broadcast networks root through nearly a hundred pilots, trying to decide which ones deserve to become series, we'd like to offer our extremely early bets on which will get the green light for 2013-14. We're making our predictions based on the talent and creators involved, each network's needs and, well, what looks cool.

Consult out our list of every broadcast network pilot to look for shows you think we missed. Until then, here's our network-by-network list of what we consider the best prospects for next season. (Click on logos for each network's individual pilot grid.)

If any of these shows don't make it to air next season, we'll eat our hat. (Which is made of candy. We can't predict hits with 100 percent accuracy any better than the networks can.)

Here we go with ABC and CBS. Check back tomorrow for The CW, Fox and NBC.

ABC needs hits to stay ahead of NBC, which managed to tie it for third place last year. Reality shows, from "The Bachelor" to "Dancing With the Stars," are losing their once-big audiences. What better time for ABC to draw on its corporate synergy with Disney and Marvel?

Here are ABC's best shots, as we see them:

"S.H.I.E.L.D."

The case for: If ABC can't make "S.H.I.E.L.D." a hit show, it should give up. This offshoot of last year's big-screen blockbuster, "The Avengers," would air after this summer's "Iron Man 3." The series has a simple hook, legions of fans who grew up with the Marvel Universe, and "Avengers" director Joss Whedon at the helm.

It would be nice if Samuel L. Jackson could stop in for special episodes, but if not, Clark Gregg is a perfectly likeable lead. And comic book shows - from AMC's "Walking Dead" to CW's "Arrow" - are hot. ABC Entertainment boss Paul Lee has fast-tracked this one for good reason.

The case against: TV shows can't afford the CGI craziness of major movie releases. But Marvel has always been about underdogs overcoming comically terrible odds. Gamma rays, pumpkin bombs and cosmic cubes are just a backdrop.

"TROPHY WIFE"

The case for: Its cast and creators. Malin Akerman, Bradley Whitford and Marcia Gay Harden are all welcome presences, and writers Emily Halpern and Sarah Haskins have served ABC well on "Private Practice." The sitcom's setup is simple and provides lots of opportunity for stories: Reformed party girl (Akerman) falls for a man (Whitford) with manipulative kids and two judgmental ex-wives.

The case against: "Private Practice" wasn't our thing. But lots of people liked it. We accept that.

ANYTHING ELSE?

The casting of Rob Corddry and Moshe Kasher on "Spy" is promising, and we like the absurd idea of a dad inadvertently joining the Secret Service to impress his son. We also have high hopes for "Super Fun Night" from Conan O'Brien and the very funny Rebel Wilson. It's not promising that CBS passed on it last season, or maybe it is: CBS isn't known for having the hippest audience.

"Awake" creator Kyle Killen's ideas are always intriguing. His new "Influence" is about two brothers running an agency that helps clients using human motivation and manipulation. But Killen's concepts - and characters who never beg to be loved - leave many viewers cold. And this doesn't sound like one of his cuddlier ideas.

We also have high hopes for "Super Fun Night" from Conan O'Brien and the very funny Rebel Wilson. It's not promising that CBS passed on it last season, or maybe it is: CBS isn't known for having the hippest audience.

"Awake" creator Kyle Killen's ideas are always intriguing. His new "Influence" is about two brothers running an agency that helps clients using human motivation and manipulation. But Killen's concepts - and characters who never beg to be loved - leave many viewers cold. And this doesn't sound like one of his cuddlier ideas.

CBS has the deepest bench of any network: Despite aging dramas and no new hits, it has no surefire candidates for cancelation - and plenty of pilots that could join its lineup.

CBS has 24 pilots, up from 15 last season. No other network has gone for so drastic an increase. But CBS also has few places to put them, which makes the competition among its pilots especially intense.

Here are what we consider CBS's best prospects:

"CRAZY ONES"

The case for: We have no idea why Robin Williams signed on to a sitcom. Yes, we know he's doing less movie work lately. But he remains an Oscar-winning actor and popular standup whose greatest gift is the kind of manic improvisation he might not get to do on a tightly scripted show by David E. Kelley.

But hey, if he wants to do this, we're sure people will watch. Sarah Michelle Gellar has signed on to play his daughter, and the series follows their characters as they work together in advertising. So maybe we'll get to see Williams' take on Don Draper's "It's not called the wheel, it's called the carousel" speech.

The case against: We wish this were a drama with comedic elements, like Kelley's "Boston Legal," "The Practice," and "Ally McBeal." Williams and Gellar's dramatic chops may be wasted on a sitcom.

"MOM"

The case for: This story of a newly sober single mom trying to pull herself together in Napa Valley (instant conflict alert) has a good cast in Anna Faris and Allison Janney. Also, it comes from Chuck Lorre, who might reasonably expect carte blanche from CBS at this point, given his hand in "Two and a Half Men," "The Big Bang Theory," and "Mike and Molly."

The case against: We know. "Two and a Half Men" can be pretty stupid. And the sobriety thing doesn't sound all that funny. But Lorre wrung solid laughs from people finding love at an Overeaters Anonymous meeting on "Mike & Molly," so we're predicting an easy green light here.

UNTITLED JIM GAFFIGAN PROJECT

The case for: Jim Gaffigan is funny. So is his co-creator, "Rescue Me" vet Peter Tolan. And so is Mira Sorvino, who has an Oscar. An Oscar, folks.

The case against: We know: The setup sounds a little "According to Jim." Schlubby regular guy, seemingly out-of-his-league wife, kids. But this time there's a much funnier Jim in the lead. And more kids: Five of 'em. And it takes place in New York City. Five kids in New York City? A little darkness with your humor? Don't hold the old Jim's sins against Gaffigan.

N.C.I.S. SPINOFF

The case for: "N.C.I.S.," "N.C.I.S.: L.A."

The case against: You thought we were going to say those two shows again, didn't you? Love or hate the franchise, it gets viewers galore. CBS is already planning to launch the spinoff with an episode of "N.C.I.S.: L.A." this spring. Look, this is happening. It just is.

ANYTHING ELSE?

How deep is the CBS bench? So deep that we're not sure a long-planned "Beverly Hills Cop" series will get on the field. Why? Because imagine "Beverly Hills Cop" without Murphy. Yes, he reprises the role of Axel Foley in "The Shield" creator Shawn Ryan's pilot. But later episodes would focus of his son, Aaron, played by Brandon T. Jackson.

Aaron has some of his dad's flair: In the pilot script, he deliberately gets himself racially profiled, just so he can ask the cops for directions. But overall, the script feels a lot like CBS continuing to prove it can turn anything into a procedural. The charm of the movies wasn't the usual cop-story grittiness: It was Murphy undercutting it. So as much as this might look like a sure thing, we're withholding judgment.

We're keeping a close eye, meanwhile, on "The Ordained," about a Kennedyesque political clan. It has great leads in "Boardwalk Empire" vet Charlie Cox and "Lost" teddy bear Jorge Garcia.

Source: http://news.yahoo.com/pilot-season-thewraps-best-bets-part-195138845.html

imbibe msg network ray j anthony shadid gary carter this means war bobby brown

Arkansas woman arrested after fleeing police in Power Wheels toy truck

(Fisher Price)Police in Arkansas have arrested a woman on DWI charges after she allegedly tried to flee the scene of a car accident in a battery-powered children?s toy truck.

Initially, 29-year-old Jamie Jeanette Craft crashed into a mobile home in her 2001 Pontiac Grand Am. But local affiliate KAIT8 reports that Craft then attempted to drive away from the scene in a very different vehicle: a Power Wheels children?s truck.

The Fisher-Price Power Wheels vehicles are made to resemble real-life, adult vehicles, including a Ford Mustang and a Jeep Wrangler. But some models are purely imaginative, including one model that is built to resemble the ?Lightning McQueen? character from the Pixar movie ?Cars.?

When the owner of the mobile home went back outside after checking on his grandchildren, he said Craft was still sitting in the toy truck, ?trying to drive it.?

Some Power Wheels models, like the Ford F150 truck, can achieve speeds of up to 5 mph. Fast enough to keep most young kids entertained but a little slow for an effective high-speed getaway.

Police described Craft as being ?irate and very intoxicated? when they arrived at the scene, according to a report filed by Officer Scott Byrd.

Craft faces several charges, including public intoxication and disorderly conduct.

Source: http://news.yahoo.com/blogs/sideshow/arkansas-woman-arrested-fleeing-police-power-wheels-toy-211908877.html

kirby sarah palin cbi the shins atomic clock daylight savings time john mccain

Monday, March 4, 2013

Big Sean Swerves Into #6 'Hottest MC In The Game' Spot

In an unprecedented move, the Detroit rapper jumps two spots from #8 to land at #6, besting A$AP Rocky and mentor Kanye.
By MTV News staff


Big Sean
Photo: Getty Images

Source: http://www.mtv.com/news/articles/1702922/hottest-mcs-2013-big-sean.jhtml

Ned Rocknroll Norman Schwarzkopf Avery Johnson netflix iTunes Alfred Morris weight watchers

Prospective study finds many children with retinoblastoma can safely forego adjuvant chemotherapy

Prospective study finds many children with retinoblastoma can safely forego adjuvant chemotherapy [ Back to EurekAlert! ] Public release date: 4-Mar-2013
[ | E-mail | Share Share ]

Contact: Nicole Racadag
nicole.racadag@asco.org
571-483-1354
American Society of Clinical Oncology

In this News Digest:

  • Summary of a study being published online March 4, 2013 in the Journal of Clinical Oncology, reporting that in certain children with retinoblastoma, adjuvant chemotherapy can be avoided, without risking disease worsening or relapse.
  • The findings will help decision-making about adjuvant treatment and therapy selection for patients with low- , intermediate-, and high-risk retinoblastoma affecting only one eye
  • Quote for attribution to ZoAnn Eckert Dreyer, MD, American Society of Clinical Oncology Cancer Communications Committee member and pediatric cancers expert
  • Links to additional resources on Cancer.Net, ASCO's cancer information Website

New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need postoperative (adjuvant) chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment, or perhaps forego it altogether. Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer.

Retinoblastoma is a rare form of cancer, accounting for three percent of all cancers diagnosed in children under the age of 15. An estimated 300 cases of retinoblastoma will be diagnosed in the United States this year, most before the age of five years. The tumor begins in the retina, a thin layer of nerve tissue that coats the back of the eye.

About two thirds of children with retinoblastoma have unilateral disease, meaning that only one eye is affected by the tumor. In developed countries, this type of disease is typically detected around two years of age. More than 95 percent of such patients are cured by surgical removal or the affected eyeball, with eyesight preserved in the other eye. However, some patients remain at risk of disease spreading and recurrence.

To estimate the risk of disease recurrence and metastasis, doctors examine the surgically removed eye under a microscope and classify the tumor as either low-, intermediate-, or high-risk. All patients whose tumors are considered high-risk receive intensive postoperative chemotherapy and radiation therapy. There is no general consensus, however, on the need for adjuvant therapy and the optimal treatment approach for patients in the other two risk categories. Therefore, protocols for adjuvant chemotherapy use in these patient groups have varied widely.

"Our study confirms that it is not necessary to give adjuvant treatment to many children with unilateral retinoblastoma," said lead study author Isabelle Aerts, MD, a pediatric oncologist at Institut Curie in Paris, France. "I think that our results will help establish the standard of care for such patients, reducing variations in postoperative chemotherapy protocols."

In the present study, 123 patients with unilateral, non-hereditary retinoblastoma were assigned to one of three risk groups according to previously established criteria. The median age at the time of eye removal surgery was 23 months. The 70 patients with low-risk disease received no postoperative chemotherapy; the 52 patients with intermediate-risk disease received four courses of adjuvant chemotherapy (etoposide, carboplatin, vincristine, cyclophosphamide), and the only patient with high-risk disease received six courses of high-dose adjuvant therapy (etoposide, carboplatin, thiotepa, vincristine, and cyclophosphamide).

At a median follow-up period of 71 months, all patients were alive. None of the patients experienced disease worsening, relapse, distant metastasis or secondary cancers. The adjuvant chemotherapy was safe overall. These data confirm that the specific regimens administered in this study, which are already being used around the world, are very effective and safe.

The excellent outcomes observed in this study confirm it is safe for patients with low-risk disease to go without adjuvant therapy and suggest that it may be safe to reduce the intensity of or even eliminate adjuvant chemotherapy in some patients with intermediate-risk disease, specifically those with a risk feature known as isolated choroidal invasionspreading of tumor cells to the layer of blood vessels and connective tissue at the back of the eye. However, more research is needed to establish clinical criteria for identifying such patients. As all patients were alive at the end of the follow up period, it is not clear whether adjuvant treatment played a vital role, or if surgery would have been sufficient.

Aerts and her research team have recently launched a new study to confirm these results and also determine if treatment could be reduced in some patients in the intermediate-risk category. In this ongoing study, patients with intermediate-risk disease and isolated choroidal invasion are being treated with only two cycles of adjuvant chemotherapy.

ASCO Perspective

ZoAnn Eckert Dreyer, MD, ASCO Cancer Communications Committee member and pediatric cancers expert

"While this study does not include a novel therapy, it demonstrates that with improved, refined risk stratification, it may be possible to reduce chemotherapy in some patient groups particularly those with intermediate-risk disease. Physicians and parents can be reassured that many children can go without aggressive chemotherapy and be spared from its long- and short-term effects. This will potentially result in a change in the standard of care for these patients."

###

Helpful Resources from Cancer.Net, ASCO's cancer information website:

  • Guide to Retinoblastoma
  • Cancer in Children
  • Understanding Chemotherapy
  • Making Decisions About Cancer Treatment

An interactive history of cancer research advances, including those in pediatric cancers, can be found at ASCO's Cancer Progress website at www.cancerprogress.net.

The Journal of Clinical Oncology is the tri-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), the world's leading professional society representing physicians who treat people with cancer.

ATTRIBUTION TO THE JOURNAL OF CLINICAL ONCOLOGY IS REQUESTED IN ALL NEWS COVERAGE.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Prospective study finds many children with retinoblastoma can safely forego adjuvant chemotherapy [ Back to EurekAlert! ] Public release date: 4-Mar-2013
[ | E-mail | Share Share ]

Contact: Nicole Racadag
nicole.racadag@asco.org
571-483-1354
American Society of Clinical Oncology

In this News Digest:

  • Summary of a study being published online March 4, 2013 in the Journal of Clinical Oncology, reporting that in certain children with retinoblastoma, adjuvant chemotherapy can be avoided, without risking disease worsening or relapse.
  • The findings will help decision-making about adjuvant treatment and therapy selection for patients with low- , intermediate-, and high-risk retinoblastoma affecting only one eye
  • Quote for attribution to ZoAnn Eckert Dreyer, MD, American Society of Clinical Oncology Cancer Communications Committee member and pediatric cancers expert
  • Links to additional resources on Cancer.Net, ASCO's cancer information Website

New results from a prospective clinical trial conducted in France show that children with low-risk retinoblastoma do not need postoperative (adjuvant) chemotherapy to prevent disease recurrence or metastasis; the results also suggest that certain patients with intermediate-risk disease can receive less aggressive adjuvant treatment, or perhaps forego it altogether. Avoiding chemotherapy spares patients from treatment side effects and long-term health risks, such as cardiovascular disease and development of a second cancer.

Retinoblastoma is a rare form of cancer, accounting for three percent of all cancers diagnosed in children under the age of 15. An estimated 300 cases of retinoblastoma will be diagnosed in the United States this year, most before the age of five years. The tumor begins in the retina, a thin layer of nerve tissue that coats the back of the eye.

About two thirds of children with retinoblastoma have unilateral disease, meaning that only one eye is affected by the tumor. In developed countries, this type of disease is typically detected around two years of age. More than 95 percent of such patients are cured by surgical removal or the affected eyeball, with eyesight preserved in the other eye. However, some patients remain at risk of disease spreading and recurrence.

To estimate the risk of disease recurrence and metastasis, doctors examine the surgically removed eye under a microscope and classify the tumor as either low-, intermediate-, or high-risk. All patients whose tumors are considered high-risk receive intensive postoperative chemotherapy and radiation therapy. There is no general consensus, however, on the need for adjuvant therapy and the optimal treatment approach for patients in the other two risk categories. Therefore, protocols for adjuvant chemotherapy use in these patient groups have varied widely.

"Our study confirms that it is not necessary to give adjuvant treatment to many children with unilateral retinoblastoma," said lead study author Isabelle Aerts, MD, a pediatric oncologist at Institut Curie in Paris, France. "I think that our results will help establish the standard of care for such patients, reducing variations in postoperative chemotherapy protocols."

In the present study, 123 patients with unilateral, non-hereditary retinoblastoma were assigned to one of three risk groups according to previously established criteria. The median age at the time of eye removal surgery was 23 months. The 70 patients with low-risk disease received no postoperative chemotherapy; the 52 patients with intermediate-risk disease received four courses of adjuvant chemotherapy (etoposide, carboplatin, vincristine, cyclophosphamide), and the only patient with high-risk disease received six courses of high-dose adjuvant therapy (etoposide, carboplatin, thiotepa, vincristine, and cyclophosphamide).

At a median follow-up period of 71 months, all patients were alive. None of the patients experienced disease worsening, relapse, distant metastasis or secondary cancers. The adjuvant chemotherapy was safe overall. These data confirm that the specific regimens administered in this study, which are already being used around the world, are very effective and safe.

The excellent outcomes observed in this study confirm it is safe for patients with low-risk disease to go without adjuvant therapy and suggest that it may be safe to reduce the intensity of or even eliminate adjuvant chemotherapy in some patients with intermediate-risk disease, specifically those with a risk feature known as isolated choroidal invasionspreading of tumor cells to the layer of blood vessels and connective tissue at the back of the eye. However, more research is needed to establish clinical criteria for identifying such patients. As all patients were alive at the end of the follow up period, it is not clear whether adjuvant treatment played a vital role, or if surgery would have been sufficient.

Aerts and her research team have recently launched a new study to confirm these results and also determine if treatment could be reduced in some patients in the intermediate-risk category. In this ongoing study, patients with intermediate-risk disease and isolated choroidal invasion are being treated with only two cycles of adjuvant chemotherapy.

ASCO Perspective

ZoAnn Eckert Dreyer, MD, ASCO Cancer Communications Committee member and pediatric cancers expert

"While this study does not include a novel therapy, it demonstrates that with improved, refined risk stratification, it may be possible to reduce chemotherapy in some patient groups particularly those with intermediate-risk disease. Physicians and parents can be reassured that many children can go without aggressive chemotherapy and be spared from its long- and short-term effects. This will potentially result in a change in the standard of care for these patients."

###

Helpful Resources from Cancer.Net, ASCO's cancer information website:

  • Guide to Retinoblastoma
  • Cancer in Children
  • Understanding Chemotherapy
  • Making Decisions About Cancer Treatment

An interactive history of cancer research advances, including those in pediatric cancers, can be found at ASCO's Cancer Progress website at www.cancerprogress.net.

The Journal of Clinical Oncology is the tri-monthly peer-reviewed journal of the American Society of Clinical Oncology (ASCO), the world's leading professional society representing physicians who treat people with cancer.

ATTRIBUTION TO THE JOURNAL OF CLINICAL ONCOLOGY IS REQUESTED IN ALL NEWS COVERAGE.


[ Back to EurekAlert! ] [ | E-mail | Share Share ]

?


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.


Source: http://www.eurekalert.org/pub_releases/2013-03/asoc-psf030413.php

divine mercy chaplet albert pujols the shining mariano rivera mariano rivera jobs report tiger woods masters 2012

Leg injury cuts short female kicker's NFL tryout

Lauren Silberman boots the ball during kicker tryouts at an NFL football regional combine workout, Sunday, March 3, 2013, at the New York Jets' training facility in Florham Park, N.J. (AP Photo/Mel Evans)

Lauren Silberman boots the ball during kicker tryouts at an NFL football regional combine workout, Sunday, March 3, 2013, at the New York Jets' training facility in Florham Park, N.J. (AP Photo/Mel Evans)

Lauren Silberman boots the ball during kicker tryouts at the NFL football regional combine workout Sunday, March 3, 2013, in Florham Park, N.J. (AP Photo/Mel Evans)

Lauren Silberman boots the ball during kicker tryouts at the NFL football regional combine workout Sunday, March 3, 2013, in Florham Park, N.J. (AP Photo/Mel Evans)

Lauren Silberman addresses reporters after taking two attempts during kicker tryouts at an NFL football regional combine workout, Sunday, March 3, 2013, at the New York Jets' training facility in Florham Park, N.J. (AP Photo/Mel Evans)

Lauren Silberman ices her thigh after taking two attempts during kicker tryouts at an NFL football regional combine workout, Sunday, March 3, 2013, at the New York Jets' training facility in Florham Park, N.J. (AP Photo/Mel Evans)

(AP) ? Frustrated and maybe a bit embarrassed, Lauren Silberman fought back tears after kicking her way into NFL history.

She became the first woman to try out at a regional combine Sunday, but she lasted all of two kicks ? none of which traveled even 20 yards. The 28-year-old Silberman hurt her right quadriceps while preparing for the tryout earlier in the week, and attributed her struggles to that injury.

"I tried staying off it and waited for today," she said. "I didn't even take kicks in warm-ups, and, it's pretty hard to know that you'll be in pain, and I wanted to work through it and I certainly tried to, but I just couldn't do it today."

While some fans on Twitter praised her for breaking through in a male-dominated sport, others wondered if this was just a publicity stunt. Regardless, the NFL got plenty of attention on a Sunday in March for one of its regional combines ? something most media normally ignore.

"I'm just really happy I had this amazing experience," Silberman said. "I might be the first woman trying out for the NFL, but I certainly hope I'm not the last."

With the 36 other kickers ? all male ? a handful of scouts and more than two dozen media watching in complete silence at the New York Jets' practice facility, Silberman winced as she attempted her first kickoff and the ball traveled only 19 yards.

She grabbed at her right leg, and then struggled for about 20 seconds to place the football on the tee before measuring her steps and trying a second kick.

It went about 13 yards.

She then asked to see a trainer and left the practice field, and appeared to be favoring her right leg.

"They certainly didn't go as far as they were in practices," Silberman said, "but I tried to work through the pain."

She wouldn't reveal how long her kicks were in the weeks leading up to the tryout.

"It's still hard to exactly say, but I just got better day by day," she said with a smile. "The distance is getting there."

Silberman is a former club soccer player at Wisconsin and ex-graduate student at MIT. While she never kicked a football in a competitive game, the NFL said Silberman qualified for the regional combine because of her athletic background.

"Our job is to evaluate talent and not leave any stone unturned," said Stephen Austin, the NFL's director of regional combines. "We want young, athletic people who have played a sport, typically in college or military or small schools."

The regional combines began in 2011, and include players who weren't among the 333 invited to the main combine in Indianapolis. The NFL is holding these sessions in 10 cities this offseason, with the most impressive players advancing to a super-regional in Dallas in April.

Silberman paid a registration fee ? $275 ? and just needed to show up Sunday and take her best shot at impressing scouts.

"Until they get here, we don't have any idea of what they're really going to turn out to do and how they're going to perform," Austin said.

When asked if he could evaluate Silberman's performance, Austin said: "That evaluation is completely incomplete."

Silberman, who spoke for just 3 minutes after the tryout, insisted she can "do more" and "it's too bad that this happened." She called the scene "surreal," adding that she "did the right thing for my body" by not continuing and anticipates trying to kick again in the future ? possibly at another regional combine next year.

"I've always been an athlete, and I've always been a gamer," she said, her eyes tearing up. "When I had the opportunity to be in the NFL, one of the world's most competitive leagues, I absolutely had to take the chance."

Silberman began her big day by waiting outside the facility around noon with all the other kickers, whose names were read off alphabetically as they entered the indoor practice field. Each participant was then given time to warm up before being broken into groups to attempt three kickoffs and then a set of five field goals, the first starting from 35 yards all the way up to 55 yards.

The 5-foot-6 Silberman, with her long brown hair pulled into a ponytail, jogged up and down the sideline during warm-ups, trying to get loose as photographers and camera crews from the likes of E! Entertainment network followed her every move.

By the time her group was called, nearly 3 hours after she arrived, Silberman ? wearing a black T-shirt with her player tag No. 68 on the front and back and white socks pulled up to her knees ? stretched her legs, did some push-ups and a few sit-ups. She then chatted a bit with Sonny Powell, another former soccer player from Charlotte, as she waited for her turn to kick.

"In talking to some of the other guys out here, I don't think her being a girl had anything to do with it," Powell said. "We're all playing for a job here and everybody's nerves were going crazy."

Silberman's goal was to try a 60-yard field goal. That was squashed just minutes into her tryout.

"You know, the distance wasn't there, but hopefully the scouts will notice my technique," she said. "It's not always length."

Silberman left the complex soon after that.

"I would certainly be very, very excited and happy if I had the opportunity to try again," she said, "but it's not up to me. It's up to the scouts."

Associated Press

Source: http://hosted2.ap.org/APDEFAULT/347875155d53465d95cec892aeb06419/Article_2013-03-04-FBN-Female-Kicker/id-cfd34ecd79af473ea0206e5c80e99570

Johnny Lewis yom kippur yom kippur avengers soa andy williams andy williams

Sunday, March 3, 2013

Is Massachusetts more racist than Mississippi, as Chief Justice Roberts hints?

In deciding whether to strike down a portion of the Voting Rights Act, the Supreme Court is focusing on whether the South has redeemed its racist history. Massachusetts, though, has a quibble with Chief Justice Roberts.

By Patrik Jonsson,?Staff writer / March 2, 2013

Assistant Poll Manager Kim Abenatha helps voters line up at the Crossroads Presbyterian Church in Stone Mountain, Ga. on Election Day 2012.

Kent D. Johnson/Atlanta Journal-Constitution/AP

Enlarge

Massachusetts officials came out swinging this week after Chief Justice John Roberts argued in a hearing on the constitutionality of a part of the Voting Rights Act of 1965 that Mississippi may be more sensitive to black voting rights than Massachusetts.

Skip to next paragraph

' + google_ads[0].line2 + '
' + google_ads[0].line3 + '

'; } else if (google_ads.length > 1) { ad_unit += ''; } } document.getElementById("ad_unit").innerHTML += ad_unit; google_adnum += google_ads.length; return; } var google_adnum = 0; google_ad_client = "pub-6743622525202572"; google_ad_output = 'js'; google_max_num_ads = '1'; google_feedback = "on"; google_ad_type = "text"; google_adtest = "on"; google_image_size = '230x105'; google_skip = '0'; // -->

That's important because Mississippi, often derided as a backwards backwater due to its ugly racial history, has to run any changes to its voting laws by the US Department of Justice, while Massachusetts, broadly seen as a paragon of the enlightened North, does not.

The argument cuts to the bone of what's in front of the Supreme Court in the case of Shelby County, Ala. v. Holder: Should the South continue to be punished for its past racism despite evidence that those days are gone, or is there another, broader imperative that Section 5 protections are necessary to guarantee the franchise for all Americans?

Section 5 requires that 9 states and many other jurisdictions, mostly in the South but also including parts of the Bronx, "pre-clear" voting law changes with the US Justice Department due to evidence of past disenfranchisement.

While Congress handily reauthorized the VRA in 2006 for another 25 years, conservative justices on the Supreme Court, including Chief Roberts, zeroed in this week on whether Section 5 has itself become discriminatory, since many indices suggest that blacks vote at equal or even higher rates than whites in the covered jurisdictions.

Justice Roberts pointed out as proof that Massachusetts, for example, has "the worst ratio of white voter turnout to African-American voter turnout."

Claiming Roberts is obfuscating US Census data, Massachusetts voting officials shot back.

"The concept of black communities in Massachusetts not voting is an old slur, and it?s not true,? Secretary of State William Galvin said. ?I guess the point [Roberts] is trying to make is Mississippi is doing so much better they don?t need the Voting Rights Act. He can still relay that conclusion, but he shouldn?t be using phony statistics. It?s deceptive, and it?s truly disturbing.?

As it is, Roberts is reading Census figures that partially support his contention, but he failed to include margins of error that could, also technically, put Massachusetts ahead of Mississippi when it comes to minority participation versus white. Also, officials noted, several other states have similar disparities as Massachusetts. At the same time, three Sec. 5 jurisdictions ? Mississippi, Georgia and North Carolina ? today have higher proportions of blacks voting than whites.

Source: http://rss.csmonitor.com/~r/feeds/csm/~3/NQNZ2FgzKNg/Is-Massachusetts-more-racist-than-Mississippi-as-Chief-Justice-Roberts-hints

super bowl kick off chili recipes carlos condit diaz vs condit super bowl 2012 kickoff time football score ron paul nevada

Misplaced molecules: New insights into the causes of dementia

Mar. 1, 2013 ? A shortage of a protein called TDP-43 caused muscle wasting and stunted nerve cells. This finding supports the idea that malfunction of this protein plays a decisive role in ALS and FTD. The study is published in the Proceedings of the National Academy of Sciences (PNAS).

ALS is an incurable neurological disease which manifests as rapidly progressing muscle wasting. Both limbs and respiratory muscles are affected. This leads to impaired mobility and breathing problems. Patients commonly die within a few years after the symptoms emerged. In rare cases, of which the British physicist Stephen Hawking is the most notable, patients can live with the disease for a long time. In Germany estimates show over 150,000 patients suffering from ALS -- an average of 1 in 500 people.

Proteins gone astray

Over the last few years, there has been increasing evidence that ALS and FTD -- a form of dementia associated with changes in personality and social behaviour -- may have similar or even the same origins. The symptoms overlap and common factors have also been found at the microscopic level. In many cases, particles accumulate and form clumps in the patient's nerve cells: this applies particularly to the TDP-43 protein.

"Normally, this protein is located in the cell nucleus and is involved in processing genetic information," explains molecular biologist Dr. Bettina Schmid, who works at the DZNE Munich site and at LMU. "However, in cases of disease, TDP-43 accumulates outside the nucleus forming aggregates." Schmid explains that it is not yet clear whether these clumps are harmful. "However, the protein's normal function is clearly disrupted. It no longer reaches the nucleus to perform its actual task. There seems to be a relationship between this malfunction and the disease."

Studies on zebrafish

However, until now little was known about the function of TDP-43. What are the consequences when this protein becomes non-functional? In order to answer this question, the team led by Bettina Schmid cooperated with the research group of Prof. Christian Haass to investigate the larvae of specially bred zebrafish. Their genetic code had been modified in such a way that no TDP-43 was produced in the organism of the fish. The result: the young fish showed massive muscle wasting and died a few days after hatching. Moreover, the extensions of the nerve cells which control the muscles were abnormal.

"To some extent, these are symptoms typical of ALS and FTD. Therefore, a loss of function of TDP-43 does seem to play a critical role in the disease," says Haass, Site Speaker of the DZNE Munich Site and chair of Metabolic Biochemistry at LMU.

The study revealed one more finding which surprised the researchers: the blood flow of the fish was massively disturbed. "It is well known that circulatory disorders play a part in other forms of dementia, notably in the case of Alzheimer's," says Haass. "We now want to investigate whether such problems with blood flow may be a general problem of neurodegenerative diseases and whether such problems occur particularly in patients with ALS and FTD."

Share this story on Facebook, Twitter, and Google:

Other social bookmarking and sharing tools:


Story Source:

The above story is reprinted from materials provided by Helmholtz Association of German Research Centres, via EurekAlert!, a service of AAAS.

Note: Materials may be edited for content and length. For further information, please contact the source cited above.


Journal Reference:

  1. B. Schmid, A. Hruscha, S. Hogl, J. Banzhaf-Strathmann, K. Strecker, J. van der Zee, M. Teucke, S. Eimer, J. Hegermann, M. Kittelmann, E. Kremmer, M. Cruts, B. Solchenberger, L. Hasenkamp, F. van Bebber, C. Van Broeckhoven, D. Edbauer, S. F. Lichtenthaler, C. Haass. Loss of ALS-associated TDP-43 in zebrafish causes muscle degeneration, vascular dysfunction, and reduced motor neuron axon outgrowth. Proceedings of the National Academy of Sciences, 2013; DOI: 10.1073/pnas.1218311110

Note: If no author is given, the source is cited instead.

Disclaimer: This article is not intended to provide medical advice, diagnosis or treatment. Views expressed here do not necessarily reflect those of ScienceDaily or its staff.

Source: http://feeds.sciencedaily.com/~r/sciencedaily/top_news/~3/1TV9qXbG57k/130302125402.htm

westminster kennel club dog show jeremy lin game winner chocolate covered strawberries shrimp scampi kate upton si cover lobster recipes hearts